Application of polydatin in preparation of pharmaceuticals for preventing and treating chronic glomerular diseases

A technology for glomerular diseases and polydipside, which is applied in the application field of polydipside in the preparation of drugs for the prevention and treatment of chronic glomerular diseases, can solve the problems of obvious side effects and limited improvement effect, and achieves clear regulation effect and clear composition. , the effect of good safety

Inactive Publication Date: 2012-12-19
NANJING UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The improvement effects of the above drugs a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0029] Example 1: Polydatin improves the treatment of glomerulopathy in fructose model rats.

[0030] Experimental animals: SD rats, 200-220 grams, male.

[0031] Drug preparation: use polydatin content of 20mg / tablet for the prevention or treatment of glomerular diseases, ultrasonically dispersed in normal saline, for intragastric administration, the dosage is 7.5mg / kg.

[0032] Experimental instruments: high-speed refrigerated centrifuge, tissue slicer, microplate reader, spectrophotometer, optical microscope, transmission electron microscope, etc.

[0033] Experimental model: Fructose rat model.

[0034] experimental method:

[0035] 1. Establishment of the model: After the animals adapt to the environment for 1 week, they are randomly divided into a model group and a normal group, with 30 animals in each group. Fructose rat model modeling: drinking water was given 10% fructose solution; the normal group was given tap water, the modeling cycle was 70 days.

[0036] 2. Four weeks late

Example Embodiment

[0048] Example 2: Polydatin improves the treatment of glomerulopathy in rats with glomerulosclerosis induced by adriamycin.

[0049] Experimental animals: SD rats, 200-220 grams, male.

[0050] Medicine preparation: use polydatin content of 20mg / tablet for the prevention or treatment of glomerular diseases, ultrasonically dispersed in normal saline, for intragastric administration, the dosage is 75mg / kg. Doxorubicin hydrochloride for injection (trade name: Famaxin Injection; Sufamaxia Company).

[0051] Experimental method: Focal segmental glomerulosclerosis is a common primary glomerular disease, mainly due to abnormal glomerular hemodynamics leading to podocyte damage, which is easy to progress to end-stage chronic renal failure .

[0052] 1. Establishment of the model: After the animals adapt to the environment for 1 week, they are randomly divided into a model group and a normal group, with 30 animals in each group. Rats in the model group were injected with adriamycin 2.5 mg /

Example Embodiment

[0062] Example 3:

[0063] According to the conventional preparation method, polydatin is added with water and an appropriate amount of solubilizer (polyethylene glycol 400) to dissolve, subpackage, and sterilize to prepare an oral solution for the prevention and treatment of chronic glomerular diseases with a 20mg / ml polydatin content ;

[0064] According to the conventional preparation method, polydatin and sorbitol are selected as soft capsule materials to prepare a capsule for the prevention and treatment of chronic glomerular disease with a content of 20mg / capsule of polydatin;

[0065] According to the conventional preparation method, the polydatin is added with the excipient cyclodextrin, mixed uniformly, granulated, and tableted to prepare a tablet for the prevention and treatment of chronic glomerular diseases with a content of 20 mg / tablet of polydatin.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a new pharmaceutical application of natural monomeric compound polydatin and specifically relates to an application of polydatin in preparation of pharmaceuticals for preventing and treating chronic glomerular diseases, particularly for preventing and treating progressive chronic glomerular diseases and sertoli cell cytopathic (such as glomerulosclerosis and the like) glomerular diseases. Animal experimental results show that the polydatin has obvious functions of preventing and improving the glomerulus functions and organic cause damages of a fructose model rat, and also has obvious functions of preventing and improving the urine protein and glomerulus sertoli cell damage of a glomerulosclerosis model rat. The polydatin and related adjuvants are mixed to be prepared into healthcare products or pharmaceuticals for preventing and treating glomerular diseases by a conventional preparation method; and the polydatin can be applicable to glomerulosclerosis and other diseases which relate to sertoli cell cytopathy and is capable of delaying and improving the glomerular progressive disease courses of related diseases.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products